entertainment -WSS

entertainment

author：knowledge 2025-09-06 02:06:02 - browse：83

Palm Drive at Stanford University on March 28, 2023 — Palm Drive at the entrance to Stanford University. Brian Frank for STAT

The resignation of Marc Tessier-Lavigne as president of Stanford University following an investigation into irregularities in his past research marks more than just the startling downfall of the leader of one of the nation’s top research powerhouses. The case is likely to have broader repercussions, signaling a tipping point in an ongoing and often contentious debate about how to assign blame and credit in the increasingly collaborative world of research.

Science is a team sport. And while the lab leaders, or principal investigators, often get most of the attention for biomedical breakthroughs, they seldom run experiments. That work is left to postdoctoral researchers, graduate students, and others who peer through microscopes, labor away in mouse rooms, and spend countless hours pipetting. Instead, professors play more of a managerial role, supervising, critiquing, and offering big-picture feedback on the work that goes on in their lab.

It’s a longstanding arrangement, but one that leads to a thorny question when research is challenged: Who’s to blame? STAT put that question to Stanford faculty and students while reporting earlier this year on allegations of image manipulation and other misconduct related to research in Tessier-Lavigne’s lab, as well as researchers at other institutions. The answer varied depending on whom you asked.

Graduate students stressed that since faculty have no qualms using work done in their labs to land grants, win prizes, and build prestige, they should ultimately be accountable for problems with the science done under their supervision. Faculty generally agree, at least in principle, but are often quick to say that there are limits to how closely they can scrutinize their lab’s work, and that team science is in part based on trust. It’s an argument Tessier-Lavigne cited in his own statement about his resignation.

It’s also one he said wasn’t good enough.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： Zyn nicotine pouches become unlikely player in latest culture war

WSS

How the drug

FDA advisory panel to debate high blood pressure devices

Abortion policy in the spotlight at Republican debate

Medicare drug price negotiation legal challenge met with skepticism

New clues to why women have higher risk of autoimmune disorders

Merck CEO won’t testify in Senate, citing no expertise in drug prices

Wikipedia

entertainment

hotspot

Walensky prepares to leave CDC — and Congress — behind

National associations that represent hospice owe an apology

Hollywood unions extend contract negotiations for actors

Merck CEO won’t testify in Senate, citing no expertise in drug prices

Anesthesiologist group: stop taking Ozempic before surgery

How the drug

How to save PrEP access — and even expand it

Readout Newsletter: CG Oncology IPO, Eli Lilly, Tesla, Merck

Hollywood unions extend contract negotiations for actors

Philips to halt sales of sleep apnea machines in U.S.

hotspot

Readout Newsletter: The latest on Novavax, Merck, Bluebird

CDC says it’s too soon to assess risk posed by Covid subvariant

Vivek Ramaswamy made waves in the debate, much as in biotech

Kellogg’s is going to war over Mexico’s nutrition label rules

Medicare Advantage insurers face 0.2% cut to 2025 payments

California store owner shot dead in dispute over displaying Pride flag: Police

focus

entertainment

leisure time

Wikipedia